NEWS & MEDIA
Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, announced its Scientific Advisory Board (SAB) comprising experts in the field of bone and dental regenerative biology from the U.S. and Europe.
Oss, The Netherlands – June 16, 2016 – Osteo-Pharma BV, a Life Sciences company focusing on the development of local treatments to improve the healing of bone fractures and defects, announces today that it has received an innovation credit of up to € 2 million from the Rijksdienst voor Ondernemers (RVO), an agency executing programs for the Dutch Ministry of Economic Affairs, Agriculture and Innovation.
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-stage pre-clinical development for various projects and will start its first dental clinical trial in mid-2021.